Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Leases (2019 - 2026)

Sunshine Biopharma filings provide 5 years of Leases readings, the most recent being $778846.0 for Q4 2025.

  • On a quarterly basis, Leases fell 16.79% to $778846.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $778846.0, a 16.79% decrease, with the full-year FY2025 number at $778846.0, down 16.79% from a year prior.
  • Leases hit $778846.0 in Q4 2025 for Sunshine Biopharma, down from $820489.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $936037.0 in Q4 2024 to a low of $541468.0 in Q3 2024.
  • Median Leases over the past 4 years was $728129.0 (2023), compared with a mean of $734260.5.
  • Biggest five-year swings in Leases: fell 20.69% in 2024 and later skyrocketed 58.32% in 2025.
  • Sunshine Biopharma's Leases stood at $760409.0 in 2022, then decreased by 14.94% to $646779.0 in 2023, then surged by 44.72% to $936037.0 in 2024, then decreased by 16.79% to $778846.0 in 2025.
  • The last three reported values for Leases were $778846.0 (Q4 2025), $820489.0 (Q3 2025), and $892817.0 (Q2 2025) per Business Quant data.